Russia's advancing programme of personalised mRNA cancer vaccines has reached early clinical use while the government prepares to incorporate such treatments into its free healthcare guarantees from 2026. The moves have prompted widespread discussion about the prospect of more accessible cancer therapies, including hopes that similar approaches could eventually support lower-cost or free care in other countries.
Russian scientists report encouraging signals from initial applications and pre-clinical work, yet specialists internationally stress that substantial further evidence is needed to substantiate broader claims.
